Aptose Biosciences Inc. (APTO)
APTO Price and Sentiment
APTO Latest news
- Conference call and webcast at 5:00 pm ET today -
HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM432392021-11-04 06:00
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 20212021-10-26 07:30
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market.
Janet Clennett, CPA, appointed Vice President, Finance
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021:
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
These Penny Stocks Have Insiders Excited To Buy Right Now. The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner2021-08-06 11:30
Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aptose's second quarter update was undramatic, with management indicating that they've fully enrolled their Phase I luxeptinib studies at 750mg and are moving on to 900mg. Dose escalation awaits in the APTO-253 AML/MDS study, but management is also going to start enrolling patients with certain eligible B-cell cancers.